Abstract
Long non-coding RNAs (lncRNAs) are a heterogeneous group of ncRNAs with characteristic size of more than 200 nucleotides. An increasing number of lncRNAs have been found to be dysregulated in many human diseases particularly cancer. However, their role in carcinogenesis is not precisely understood. DLX6-AS1 is an lncRNAs which has been unveiled to be up-regulated in various number of cancers. In different cell studies, DLX6-AS1 has shown oncogenic role via promoting oncogenic phenotype of cancer cell lines. Increase in tumor cell proliferation, migration, invasion, and EMT while suppressing apoptosis in cancer cells are the effects of DLX6-AS1 in development and progression of cancer. In the majority of cell experiment, mediator miRNAs have been identified which are sponged and negatively regulated by DLX6-AS1, and they in turn regulate expression of a number of transcription factors, eventually affecting signaling pathways involved in carcinogenesis. These pathways form axes through which DLX6-AS1 promotes carcinogenicity of cancer cells. Xenograft animal studies, also have confirmed enhancing effect of DLX6-AS1 on tumor growth and metastasis. Clinical evaluations in cancerous patients have also shown increased expression of DLX6-AS1 in tumor tissues compared to healthy tissues. High DLX6-AS1 expression has shown positive association with advanced clinicopathological features in cancerous patients. Survival analyses have demonstrated correlation between high DLX6-AS1 expression and shorter survival. In cox regression analysis, DLX6-AS1 has been found as an independent prognostic factor for patients with various types of cancer.
Introduction
In complex organisms, genome sequencing analyses have unveiled that just a small fraction of genome (e.g., 1–2% for mammals) encodes for protein via coding RNAs or messenger RNAs (mRNAs) that are located in the middle of central dogma making connection between DNA and corresponding protein. These protein-coding regions are those which have been described as genes for more than half a century in biology literature. However, the majority of large genomes i.e., more than 80% is transcribed to non-coding RNAs (ncRNAs) for which no corresponding protein have been found, but a huge number of regulatory functions are recognized. Unlike the primary expectations which termed ncRNAs as “junk” DNA without biological importance, today it is clarified that they are involved in gene regulation at transcriptional and post-transcriptional levels, and through which they play critical roles in a vast number of biological processes such as imprinting, methylation, and silencing via several interactions with DNA, RNA, and proteins (Mattick, 2001). Based on size and function of transcripts, ncRNAs are categorized in several classes including microRNAs (miRNAs), small interfering RNAs (siRNAs), PIWI-interacting RNAs and long ncRNAs (lncRNAs). Transcripts of more than 200 nucleotide length are classified as lncRNAs which were primarily reported by Okazaki et al. in an analysis of mouse transcriptome in 2002 (Okazaki et al., 2002). RNA polymerase II is predominantly responsible for transcription of lncRNAs. They mainly endure capping, polyadenylation, splicing after transcription, and also trimethylation on histone 3 corresponding to lysine 4 (H3K4me3) (Losko et al., 2016; Bertone et al., 2004; Guttman et al., 2009). Thousands of heterogenous lncRNAs have been identified in multicellular organisms [60,000 encoding loci in human genome (Iyer et al., 2015)] showing tissues specificity which is also conserved during evolution (Necsulea et al., 2014) and acting as regulators of gene expression both in nucleus or cytoplasm (Fatica and Bozzoni, 2014) suggesting their involvement in specific biologic processes. Several databases have been created to store and provide access to an increasing number of lncRNAs. Examples of these databases are TRlnc for regulatory lncRNAs in humans (Li et al., 2020a), lncRNASNP1 and 2 for single nucleotide polymorphisms (SNPs) of human and mouse lncRNAs (Gong et al., 2014; Miao et al., 2017), LncRNA2Target v2.0 for target genes of lncRNAs (Cheng et al., 2018), CRISPRlnc for validated single guide RNAs (sgRNAs) used in clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein number 9 (Cas9) gene editing technology for lncRNAs (Chen et al., 2018) and clusLnc2Cancer for effective lncRNAs in human cancers (Ning et al., 2015). They act in cis and trans modes by gathering and localizing transcription factors to a locus. Gene expression regulation at several levels including transcription, translation and splicing, epigenetic regulation in X-chromosome inactivation or dosage compensation, genomic imprinting, involvement in developmental and differential processes, neurogenesis, regulation of cell cycle, and cell transportation are among the fundamental roles which have been recognized for lncRNAs (Mattick, 2009; Wilusz et al., 2009; Wu et al., 2013; Dey et al., 2014; Fatica and Bozzoni, 2014). Accordingly, an increasing number of lncRNAs have been associated with various types of human diseases. Dysregulation in expression levels or mutation of lncRNAs are found to play role in the pathogenesis of diseases like age-related diseases, cardiovascular diseases (Uchida and Dimmeler, 2015), kidney and liver diseases (Takahashi et al., 2014; Ignarski et al., 2019), ophthalmologic diseases (Wawrzyniak et al., 2018), neurodegenerative and other diseases affecting central nervous system (CNS) (Pastori and Wahlestedt, 2012; Wan et al., 2017), and particularly various types of cancer. Mediation of a number of cancer-associated processes like cell cycle regulation, epigenetic regulation, and involvement in signaling pathways and hormone-related pathways indicate potential roles of lncRNAs act as contributors in the development and progression of cancer (Sahu et al., 2015). MALAT1, HOTAIR, H19, HOTTIP, ANRIL, and NEAT1 are among the most famous lncRNAs which have been mostly studied in many types of cancer exhibiting dysregulation in cancer cells, tissues and body fluids of affected patients. In this review, we aim to have an overview of studies which have assessed tumorigenic effects of the lncRNA distal-less homeobox 6 antisense RNA 1 (DLX6-AS1) in three levels of cell, animal, and human studies. In humans, DLX6-AS1 gene is located on chromosome 7q21.3, primarily identified by Feng et al. (2006) to promote DLX5/6 function in trans mode. This lncRNA has been found to be up-regulated in a growing number of different types of cancerous tissues compared to normal tissues. Promoting carcinogenesis via increasing tumor cell proliferation, migration, and invasion through enhancing Epithelial–Mesenchymal Transition (EMT) along with suppression of apoptosis and chemosensitivity have been shown in cell studies of DLX6-AS1 overexpression. Enhanced tumor growth and metastasis has confirmed tumorigenic potentials of DLX6-AS1 in animal studies. Correlation between high DLX6-AS1 expression and advanced clinicopathological features and also poor prognosis and survival in cancerous patients has suggested DLX6-AS1 not only as a diagnostic and prognostic biomarker but also as a therapeutical target.
Functional Effects of DLX6-AS1 on Cell Proliferation, Apoptosis and Migration
Cancer cell lines have been used to evaluate function of DLX6-AS1 in cell cycle progression, cell proliferation and apoptosis. Moreover, high throughput RNA sequencing and also confirmation via quantitative real-time polymerase chain reaction (qRT-PCR) analyses have facilitated identification of differentially expressed lncRNAs in cancer cell lines compared to controls. In vitro experiments have shown significant increase in expression levels of DLX6-AS1 in cancer cell lines. In different cell experiment, it has been demonstrated that DLX6-AS1 overexpression promotes tumor cell proliferation, migration, and invasion, while suppressing apoptosis. In cell counting, colony formation, and 5-Bromo-2-deoxyUridine (BrdU) assays, decreased proliferation of cancer cells is reported for DLX6-AS1 knockdown. Wound healing, Matrigel and Transwell assays for assessment tumor cell migration and invasion show suppressed metastatic capability of cancerous cells under DLX6-AS1 silencing. Flowcytometry also demonstrated cell cycle arrest in treated cancer cells. Furthermore, decreased cell viability and elevated apoptosis in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), flowcytometry, and apoptotic marker assays have unveiled increased apoptosis in DLX6-AS1-silenced cancer cells. In hepatocellular carcinoma (HCC), DLX6-AS1 has been shown to be highly expressed in human HCC cell lines versus normal liver cells, while miR-513c as its downstream microRNA exhibited down-regulation indicating DLX6-AS1 acts as sponge for this miRNA (Liu et al., 2020a). Cullin4A (Cul4A) was also known as target gene of miR-513c which showed increase in expression level following DLX6-AS1 up-regulation. In other words, DLX6-AS1 elevated Cul4A expression by binding to and sponging miR-513c. Cul4A, itself positively regulated activity of annexin A10 (ANXA10). DLX6-AS1 silencing using specific short hairpin RNA (shRNA) repressed cell viability, invasion, and migration of HCC cells. Also, Cul4A knockdown was shown to inhibit tumorigenic effects of HCC cells via inhibition of ANXA10 degradation through ubiquitin-associated pathway. The results showed that DLX6-AS1 exerts its tumorigenic role via miR-513c/Cul4A/ANXA10 axis. In a distinct study (Zhang et al., 2017), DLX6-AS1 was shown to exert same tumorigenic roles in HCC cells via miR-203a/MMP-2 axis.
In other experiments, DLX6-AS1 has been shown to sponge many other miRNAs and affect transcription factors, genes or signaling pathways which eventually promotes malignant phenotypes. miRNAs which are mainly negatively regulated by up-stream DLX6-AS1 exhibit down-regulation in cancer tissues and cells, and their overexpression reverse the malignant phenotypes of DLX6-AS1 in cancer cell lines. Downstream factors demonstrate expression changes consistent with DLX6-AS1. Overexpression of these factors drives same influences with DLX6-AS1 overexpression. In a study in ovarian cancer (Kong and Zhang, 2020), miR-195-5p was shown to be down-regulated in cancer tissues and was identified as target of up-regulated DLX6-AS1. While DLX6-AS1 promoted cell proliferation, migration, and invasion in tumor cell lines, miR-195-5p overexpression reversed malignant phenotypes. Four and a half LIM domains protein 2 (FHL2) which is known to play role in development and progression of different types of cancer via activation of androgen receptor (AR or NR3C4), Wnt/β-catenin pathway or several genes was demonstrated as target of miR-195-5p. FHL2 overexpression exhibited same results on malignant phenotypes of cancer cells. In other words, DLX6-AS1 exerted its tumorigenic effects in ovarian cancer cells via miR-195-5p/FHL2 signaling axis. In bladder cancer, miR-195-5p as target of DLX6-AS1 was shown to down-regulate the vascular endothelial growth factor A (VEGFA) and consequently inhibit malignancy phenotype in cancer cells, while miR-195-5p inhibition returned the DLX6-AS1 tumorigenic effects (Zhao et al., 2020a).
Furthermore, DLX6-AS1 has been shown to up-regulated DLK1, a regulator of cell differentiation and prognostic factor for several cancers, through sponging miR-129-5p which in turn triggers Wnt signaling, and eventually promotes stemness in osteosarcoma cell lines (Zhang et al., 2018). PI3K/AKT/mTOR signaling pathway is another critical tumorigenic pathway which is known to be activated by DLX6-AS1, promoting malignant phenotype of colorectal cancer cells (Zhang et al., 2019a).
Overall, it is demonstrated that DLX6-AS1 acts as an oncogenic lncRNA enhancing malignant phenotype of several cancer cells (Figure 1).
FIGURE 1
Oncogenic role of DLX6-AS1 in different cancer types is exerted through various mechanisms, particularly sponging miRNAs.
DLX6-AS1 is oncogenic lncRNA has been found to be up-regulated in a growing number of different types of cancerous tissues compared to normal tissues. Promoting carcinogenesis via increasing tumor cell proliferation, migration, and invasion through enhancing Epithelial–Mesenchymal Transition (EMT). miRNAs have been identified which are negatively regulated by DLX6-AS1, and they regulate expression of a number of transcription factors, eventually affecting signaling pathways involved in carcinogenesis.
Table 1 shows the findings of the studies conducted on DLX6-AS1 oncogenic role in various cancer cell lines.
TABLE 1
| Cancer type | Targets/Regulators and signaling pathways | Assessed cell lines | Function | References |
|---|---|---|---|---|
| HCC | miR-513c/Cul4A/ANXA10 axis | Hep3B, HepG2, Huh7, PLC/PRF/5, and THLE-3 | Δ DLX6-AS1: ↓tumor cell viability, ↓invasion, and ↓migration | Liu et al. (2020a) |
| miR-203a/MMP-2 axis | Hep3B, MHCC97L, HCCLM3, HepG2, Huh7, and LO2 | Δ DLX6-AS1: ↓tumor cell proliferation, ↓invasion, and ↓migration | Zhang et al. (2017) | |
| Pancreas | miR-181b/ZEB2 axis | CAPAN-1, BxPC-3, SW 1990, PANC-1, and HPDE6-C7 | Δ DLX6-AS1: ↓tumor cell proliferation, ↓migration, and ↓invasion | An et al. (2018) |
| miR-497-5p/FZD4/FZD6/Wnt/β-catenin axis | Panc-1, AsPC-1, Bxpc-3, Capan-1, CFPAC-1, and MIA PaCa-2 | ↑↑ DLX6-AS1: ↑tumor cell proliferation, ↑migration, and ↑invasion, while Δ DLX6-AS1 reversed the tumorigenic effects | Yang et al. (2019a) | |
| Prostate | miR-497-5p/SNCG axis | LNCap, DU145, PC-3, VCap, and WPMY1 | Δ DLX6-AS1: ↓tumor cell proliferation, ↑apoptosis | Zhu et al. (2021) |
| DNMT1/LARGE axis | CWR22rv1, LAPC-9, DU145, LNCaP, PC-3M, and PrEC | ↑↑ DLX6-AS1: ↑tumor cell proliferation, ↑migration, and ↑invasion | Zhao et al. (2020b) | |
| Kidney (renal cell carcinoma; RCC) | miR-26a/PTEN axis | A498, ACHN, Caki-1, Caki-2, 786-O, G401, and HK-2 | Δ DLX6-AS1: ↓tumor cell proliferation, and ↓colony formation | Zeng et al. (2017) |
| Liver | miR-424‐5p/WEE1 axis | MHCC97L, HCCLM3, SK‐HEP‐1, Hep3B, Huh7, and HEK293T | Δ DLX6-AS1: ↓tumor cell proliferation, ↓migration, and ↓invasion | Li et al. (2019a) |
| CADM1/STAT3 axis | Hep3B, HepG2, SMMC-7721, HCCLM3, Huh7 and L02 | Δ DLX6-AS1: ↓self-renewal, ↓amplification, and ↓proliferation in liver cancer stem cells | Wu et al. (2019) | |
| Neuroblastoma | miR-513c-5p/PLK4 axis | SK-N-SH, SK-N-AS NB, and HUVEC | Δ DLX6-AS1: ↓tumor cell viability, ↓colony formation, ↓migration, ↓invasion, ↑apoptosis and ↑cell cycle arrest | Jia et al. (2020) |
| miR-506-3p/STAT2 axis | SK-N-SH and LAN-6 | Δ DLX6-AS1: ↓tumor cell proliferation, ↓glycolysis and ↑ cell cycle arrest at G1/S phase | Han et al. (2020) | |
| miR-497-5p/YAP1 axis | SK-N-AS, SK-N-SH, SH-SY5Y, and SK-N-BE | Δ DLX6-AS1: ↓tumor cell proliferation, ↓migration, ↓invasion, and ↓EMT | Li et al. (2020b) | |
| miR-107/BDNF axis | NB-1643, SK-N-SH, NB-1691, SK-N-AS, IMR-32, and SH-SY5Y | Δ DLX6-AS1: ↓tumor cell proliferation, ↓migration, ↓invasion, and ↑apoptosis | Li et al. (2019b) | |
| Glioma | miR-197-5p/E2F1 axis | U251, T98G, U87MG, SHG44, and NHA | Δ DLX6-AS1: ↓tumor cell proliferation, and ↓invasion | Zhang et al. (2019b) |
| Osteosarcoma | miR-129-5p/DLK1 axis | MG63 and U2OS | Δ DLX6-AS1: ↓ number and size of tumor spheres, and ↓CSCs in osteosarcoma cell lines | Zhang et al. (2018) |
| DLX6-AS1 triggers Wnt signaling | ||||
| miR-641/HOXA9 axis | Saos‐2, MG‐63, U2OS and hFOB | Δ DLX6-AS1: ↓tumor cell proliferation, ↓migration, ↓invasion, and ↑apoptosis | Zhang et al. (2019b) | |
| Endometria | DLX6 | HEC-1‐B, HHUA, HEC‐1‐A, RL‐952, and HEC‐251 | Δ DLX6-AS1: ↓tumor cell proliferation, ↓invasion, and ↑apoptosis | Zhao and Xu, (2020) |
| DLX6-AS1 up-regulated DLX6 through inducing its promotor via p300/E2F1 | ||||
| Cervix | miR-16-5p/ARPP19 Axis | SiHa, HeLa, C-33A, CaSki, and End1/E6E7 | Δ DLX6-AS1: ↓tumor cell proliferation, ↓migration, ↓EMT and ↑apoptosis | Xie et al. (2020) |
| miR-199a | CaSki, ME-180, C-33A, SiHa, HeLa, and NC104 | Δ DLX6-AS1: ↓tumor cell proliferation, ↓colony formation, ↓migration, and ↑apoptosis | Long et al. (2019) | |
| Breast | miR-505-3p/RUNX2 axis | MDA-MB-231, MDA-MB-468, BT-474, MCF-7, T47D, and MCF-10A | Δ DLX6-AS1: ↓tumor cell proliferation, ↓migration, ↓invasion, and ↑apoptosis | Zhao et al. (2019) |
| Breast (triple-negative; TNBC) | miR-199b-5p/paxillin axis | CCD-1095Sk, MDA-MB-231, HCC 1806, HCC1599, and HS578 T | Δ DLX6-AS1: ↓tumor cell proliferation, ↓EMT, ↑apoptosis, and ↓chemoresistance to cisplatin | Du et al. (2020) |
| Ovaries | miR-195-5/FHL2 axis | SKOV3, A2780, IOSE80, and 293 T | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓migration, ↓invasion, and ↑apoptosis | Kong and Zhang, (2020) |
| Notch | IOSE80, HEY, SKOV3, and OVCAR-3 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓migration, ↓invasion, and ↑apoptosis | Zhao and Liu, (2019) | |
| Bladder | miR-195-5p/VEGFA | T24, RT4, 5637, J82, SW780, and SV-HUC-1 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓migration, ↓invasion, and ↑apoptosis | Zhao et al. (2020a) |
| Wnt/β-catenin | 5637, J82, T24, and SV-HUC-1 | ↑↑DLX6-AS1: ↑ tumor cell proliferation, ↑migration, ↑invasion, and ↑EMT. Knockdown reversed the malignancy phenotype of cells | Guo et al. (2019) | |
| miR-223/HSP90B1 axis | T24, SW780, and SV-HUC-1 | Δ DLX6-AS1: ↓ tumor cell proliferation, and ↓invasion | Fang et al. (2019) | |
| Colorectal | miR-26a/EZH2 Axis | DLD-1, HCT-116, HT-29, SW480, SW620, and NCM460 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓migration, ↓invasion, and ↑cell cycle arrest | Kong et al. (2020) |
| PI3K/AKT/mTOR pathway | HCT116, HT-29, SW480, and NCM460 | ↑↑ DLX6-AS1: ↑ tumor cell proliferation, ↑migration, ↑invasion, and ↓apoptosis. Δ DLX6-AS1 returned the malignant phenotype of cancer cells | Zhang et al. (2019a) | |
| Larynx | miR-26a/TRPC3 axis | HEp-2 and Tu-177 | Δ DLX6-AS1: ↓ tumor cell proliferation via decrease in mitochondrial radical oxygen species | Liu et al. (2020b) |
| DLX6-AS1 regulates metabolism of cancer cells | ||||
| miR-376c | Hep2 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓invasion, and ↑cell cycle arrest | Yang et al. (2019b) | |
| Nasopharynx | miR‐199a‐5p/HIF‐1α | S18, S26, CNE‐1, CNE-2, HONE‐1, 5‐8F, and NP69 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓migration, and ↓invasion | Yang et al. (2020) |
| axis | ||||
| Esophagus | -- | EC109, KYSE30, and Het-1A | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓migration, ↓invasion, and ↓EMT | Zhang et al. (2019c) |
| Stomach | miR-4290/PDK1 axis | HGC-27, SGC7901, MGC803, MKN45, and GES-1 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↑apoptosis, and caused glucose metabolism impairment | Qian et al. (2021) |
| FUS/MAP4K1 axis | AGS, HGC-27, SGC-7901, BGC-823, and GES-1 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓migration, and ↓EMT | Wu et al. (2020) | |
| miR-204-5p/OCT1 axis | MGC-803, HGC-27, MKN-7, MKN-28, MKN-45, AGS, SGC-7901, and GES-1 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓migration, ↓invasion, and ↓EMT | Liang et al. (2020) | |
| -- | HGC27, BGC823, SGC7901, AGS, and GES-1 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓colony formation, ↓migration, ↓invasion, ↓EMT, and ↓cell cycle progression | Fu et al. (2019) | |
| Lung (NSCLC) | miR-144/PRR11 axis | H1975 and A549 | Δ DLX6-AS1: ↓ tumor cell proliferation, ↓migration, ↓invasion, and ↑apoptosis | Huang et al. (2019) |
| miR27b3p/GSPT1 axis | CALU3, CALU6, A549, H1299, and HBE | Δ DLX6-AS1: ↓proliferation, ↓migration, and ↓invasion | Sun et al. (2019) | |
| Ewing’s sarcoma | miR-124-3p/CDK4 axis | SK-ES-1, A673, RD-ES, and mesenchymal stem cells (MSCs) | Δ DLX6-AS1: ↓ tumor cell proliferation, and ↑apoptosis | Lei et al. (2019) |
an overview to the oncogenic influences of DLX6-AS1 in cell studies of different types of cancer.
Δ: knockdown or silencing, ↓: decrease or repression, ↑: increase or stimulation, ↑↑: overexpression, CSCs: cancer stem cells.
Impact of DLX6-AS1 in Enhancement of Tumor Growth
Experiments in animal models have confirmed oncogenic role of DLX6-AS1. It is expected that DLX6-AS1 overexpression or silencing increases or suppresses malignant features of cancer cells in xenograft models, respectively. To examine this claim, treated cells; either overexpressing or with silenced for DLX6-AS1; have been injected to the animals; mainly BALB/c nude mice, and then tumor size or volume, and metastasis in expected organ have been checked at certain intervals. Changes in chemosensitivity have also been assessed occasionally. Decreased tumor growth and metastasis, and also chemoresistance have been reported under DLX6-AS1 knockdown conditions in animal studies. Opposite findings have been reported when DLX6-AS1 was overexpressed in injected cancer cells to the nude mice. Taken together, these findings demonstrate oncogenic role of DLX6-AS1 in tumor progression and metastasis in animal studies are consistent with the results of cell studies (Table 2).
TABLE 2
| Cancer type | Animal models | Function | References |
|---|---|---|---|
| HCC | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Liu et al. (2020a) |
| BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Zhang et al. (2017) | |
| Pancreas | BABL/c athymic nude mice | Δ DLX6-AS1: ↓ tumor growth | An et al. (2018) |
| BABL/c athymic nude mice | Δ DLX6-AS1: ↓ tumor growth, and ↓metastasis | Yang et al. (2019a) | |
| Prostate | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Zhu et al. (2021) |
| SCID mice | ↑↑ DLX6-AS1: ↑tumor growth and ↑lymph node metastasis | Zhao et al. (2020b) | |
| Neuroblastoma | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Jia et al. (2020) |
| BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Han et al. (2020) | |
| BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Li et al. (2020b) | |
| BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Li et al. (2019b) | |
| Glioma | Male nude mic | Δ DLX6-AS1: ↓ tumor growth | Zhang et al. (2019b) |
| Endometria | 32 healthy nude mice | Δ DLX6-AS1: ↓ tumor growth | Zhao and Xu, (2020) |
| Cervix | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Xie et al. (2020) |
| Breast (TNBC) | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth, and ↓chemoresistance to cisplatin | Du et al. (2020) |
| Ovaries | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Kong and Zhang, (2020) |
| Bladder | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Zhao et al. (2020a) |
| Male nude mice | Δ DLX6-AS1: ↓ tumor growth | Guo et al. (2019) | |
| Larynx | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Liu et al. (2020b) |
| Stomach | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Qian et al. (2021) |
| Osteosarcoma | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Zhang et al. (2018) |
| BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Zhang et al. (2019b) | |
| Lung (NSCLC) | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Huang et al. (2019) |
| BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Sun et al. (2019) | |
| Colorectal | Female nude mice | Δ DLX6-AS1: ↓ tumor growth | Zhang et al. (2019a) |
| Liver | NOD-SCID mice | Δ DLX6-AS1: ↓tumorigenesis and ↓tumor growth | Wu et al. (2019) |
| Kidney (RCC) | BALB/c nude mice | Δ DLX6-AS1: ↓ tumor growth | Zeng et al. (2017) |
Effects of DLX6-AS1 on tumor growth and metastasis in animal studies.
Impact of DLX6-AS1 on Survival of Patients With Different Types of Cancers
Cancerous tissues resected from patients have shown significantly increased expression of DLX6-AS1 compared to matched normal adjacent tissues (NATs) and healthy people in microarray analysis and qRT-PCR. In non-small cell lung cancer (NSCLC), DLX6-AS1 high expression levels were found to be positively associated with advanced clinicopathological features including higher disease stage, tumor metastasis to lymph nodes and also weak differentiation of cancer cells in patients (Zhang et al., 2019c). Also, Guo et al. (2019) demonstrated high DLX6-AS1 expression in bladder cancer patients with advanced TNM stage, positive lymph node and distant metastases. Survival analysis via Kaplan-Meier curve has shown association between high DLX6-AS1 expression and shorter overall survival (OS), and/or disease-free survival (DFS) in several types of cancer like HCC (Liu et al., 2020a; Zhang et al., 2017), gastric cancer (Qian et al., 2021; Fu et al., 2019), glioma (Zhang et al., 2019b), breast cancer (Zhao et al., 2019), and several others (Table 3). Competitive endogenous RNA (ceRNA) network analysis has demonstrated reliability of DLX6-AS1 along with three other lncRNAs and two more miRNAs in a signature as prognostic biomarkers in HCC patients (Long et al., 2019). Ding et al. (2021) showed serum exosomal levels of DLX6-AS1 can act as a prognostic biomarker in cervical cancer patients. Also, multivariate cox regression has shown that DLX6-AS1 is an independent prognostic factor for survival in a number of cancers such as gastric cancer (Qian et al., 2021), osteosarcoma (Zhang et al., 2018), and ovarian cancer (Zhao and Liu, 2019). Furthermore, a value of 0.795 for area under curve (AUC) in receiver operating characteristic (ROC) curve has shown acceptable efficiency of DLX6-AS1 in diagnosis of glioma (Zhang et al., 2019b). Taken together, according to the clinical data, DLX6-AS1 is suggested as a potential prognostic biomarker for different types of human cancer and a putative factor to manage cancerous patients.
TABLE 3
| Cancer type | Clinical samples | Expression change in tumor tissues compared to normal tissues | Kaplan-Meier analysis | Multivariate cox regression | References |
|---|---|---|---|---|---|
| HCC | 85 cancerous patients and matched NATs | Up | Patients with high DLX6-AS1 expression had poor OS compared to those with lower levels | -- | Liu et al. (2020a) |
| 60 cancerous patients and matched NATs | Up | High DLX6-AS1 expression levels were correlated with poor OS in HCC patients compared to low levels | -- | Zhang et al. (2017) | |
| Larynx | 43 cancerous patients and matched NATs | Up | Patients with high DLX6-AS1 expression had shorter OS compared to those with lower levels | -- | Liu et al. (2020b) |
| Stomach | 60 cancerous tissues and 28 NATs | Up | High DLX6-AS1 expression levels were associated with poor OS. | DLX6-AS1 expression is an independent predictor of poor prognosis | Qian et al. (2021) |
| 375 cancerous tissues and 32 NATs | Up | -- | -- | Liang et al. (2020) | |
| 62 cancerous tissues and matched NATs | Up | High DLX6-AS1 expression levels correlated with shorter survival in gastric cancer patients compared to those with low levels | -- | Fu et al. (2019) | |
| Glioma | 36 cancerous tissues and matched NATs | Up | Patients with high DLX6-AS1 expression levels exhibited shorter OS compared to those with low levels | -- | Zhang et al. (2019b) |
| Osteosarcoma | 80 cancerous tissues and matched NATs | Up | High DLX6-AS1 expression levels were correlated with shorter OS in osteosarcoma patients compared to low levels | DLX6-AS1 expression level is an independent prognostic factor | Zhang et al. (2018) |
| Breast | 45 cancerous tissues and matched NATs | Up | High DLX6-AS1 expression levels were correlated with shorter OS in osteosarcoma patients compared to low levels | -- | Zhao et al. (2019) |
| Pancreas | 60 cancer tissues and matched NATs | Up | Patients with low DLX6-AS1 expression levels exhibited higher survival rate compared to those with high levels | -- | Yang et al. (2019a) |
| 84 cancer tissues and matched NATs | Up | -- | -- | An et al. (2018) | |
| Prostate | 20 cancer tissues and matched NATs | Up | -- | -- | Zhu et al. (2021) |
| 32 cancerous patients and 28 patients with benign prostate hyperplasia | Up | -- | -- | Zhao et al. (2020b) | |
| Neuroblastoma | 20 cancer tissues and matched NATs | Up | -- | -- | Jia et al. (2020) |
| 31 cancer tissues and matched NATs | Up | -- | -- | Han et al. (2020) | |
| 70 cancer tissues and matched NATs | Up | High DLX6-AS1 expression levels were significantly associated with shorter OS in neuroblastoma patients compared to those with low levels | -- | Li et al. (2020b) | |
| 88 cancer tissues and matched NATs | Up | High DLX6-AS1 expression levels were correlated with shorter OS in neuroblastoma patients compared to those with low levels | Li et al. (2019b) | ||
| Endometria | 78 cancer tissues and matched NATs | Up | -- | -- | Zhao and Xu, (2020) |
| Breast (TNBC) | 47 cancerous tissues and matched NATs | Up | -- | -- | Du et al. (2020) |
| Ovaries | 50 cancerous tissues and matched NATs | Up | -- | -- | Kong and Zhang, (2020) |
| 128 cancerous tissues and matched NATs | Up | Patients with high DLX6-AS1 expression levels had shorter OS and DFS compared to those with low levels | DLX6-AS1 expression is an independent prognostic factor for survival in ovarian cancer patients | Zhao and Liu, (2019) | |
| Bladder | 60 cancerous tissues and matched NATs | Up | -- | -- | Zhao et al. (2020a) |
| 54 cancerous tissues and matched NATs | Up | -- | -- | Guo et al. (2019) | |
| Colorectal | 76 cancerous tissues and matched NATs | Up | -- | -- | Kong et al. (2020) |
| 60 cancerous tissues and matched NATs | Up | -- | -- | Zhang et al. (2019a) | |
| Larynx (LSCC) | 23 cancerous tissues and matched NATs | Up | -- | -- | Yang et al. (2019b) |
| Osteosarcoma | 40 cancerous tissues and matched NATs | Up | -- | -- | Zhang et al. (2019b) |
| Lung (NSCLC) | 48 cancerous tissues and matched NATs | Up | -- | -- | Huang et al. (2019) |
| 51 cancerous tissues and matched NATs | Up | -- | -- | Sun et al. (2019) | |
| Nasopharynx | 72 cancerous tissues and matched NATs | Up | -- | -- | Yang et al. (2020) |
| Esophagus | 73 cancerous tissues and matched NATs | Up | -- | -- | Zhang et al. (2019c) |
| Liver | 30 cancerous tissues and matched NATs | Up | -- | -- | Li et al. (2019a) |
| Cervix | 78 cancerous tissues and matched NATs | Up | -- | -- | Long et al. (2019) |
| Kidney (RCC) | 15 cancerous tissues and matched NATs | Up | -- | -- | Zeng et al. (2017) |
| Ewing’s sarcoma | 20 cancerous tissues and matched NATs | Up | -- | -- | Lei et al. (2019) |
Clinical prognostic importance of DLX6-AS1 in human cancers.
Discussion
LncRNAs are a heterogeneous group of ncRNAs with characteristic size of more than 200 nucleotides. An increasing number of lncRNAs have been found to be dysregulated in many human diseases particularly cancer. However, their role in carcinogenesis is not precisely understood. DLX6-AS1 is an lncRNAs which has been unveiled to be up-regulated in a various number of cancers. In different cell studies, DLX6-AS1 has shown oncogenic role via promoting oncogenic phenotype of cancer cell lines. Increase in tumor cell proliferation, migration, invasion, and EMT while suppressing apoptosis in cancer cells are the effects of DLX6-AS1 in the development and progression of cancer. Silencing experiments using specific shRNA against DLX6-AS1 have shown suppression of tumorigenic potential. Similar pattern of expression in different types of cancer originated from various tissues not only reveals its universal function in the tumorigenesis, but also emphasizes the suitability of therapeutic modalities against this lncRNA for a wide range of human malignancies.
In the majority of cell experiments, mediator miRNAs have been identified which are negatively regulated by DLX6-AS1, and they regulate expression of a number of transcription factors, eventually affecting signaling pathways involved in carcinogenesis. These pathways form axes through which DLX6-AS1 regulates transcription factors, and/or signaling pathways eventually promotes carcinogenicity of cancer cells. Identification of functional routes of DLX6-AS1 effects in the carcinogenesis is an important step toward design of targeted therapies in cancer. It is also important to mention that these therapies should not affect pathways with crucial roles in the physiological features of normal cells.
Xenograft animal studies also have confirmed enhancing effect of DLX6-AS1 on tumor growth and metastasis. Clinical evaluations in cancerous patients have shown increased expression of DLX6-AS1 in tumor tissues compared to healthy tissues. High DLX6-AS1 expression has shown positive association with advanced clinicopathological features in cancerous patients. Survival analyses have demonstrated correlation between high DLX6-AS1 expression and shorter survival. In cox regression analysis, DLX6-AS1 has been suggested as an independent prognostic factor for patients with various types of cancer.
Animal and cell line studies have confirmed that therapeutic modalities targeting DLX6-AS1 can effectively reduce tumorigenic potential of malignant cells, induce their apoptosis and diminish tumor size and burden. However, the efficacy and safety of these methods have not been evaluated in the clinical settings.
Taken together, these findings demonstrate carcinogenic role of DLX6-AS1 in the development and progression of different human cancers suggesting diagnostic and prognostic potentials of DLX6-AS1 in human cancers. Known role of up-regulated DLX6-AS1 in cancer tissues and clinical samples also suggest therapeutic potentials in finding treatments for different types of cancer via targeting DLX6-AS1. Further studies are required to utilize diagnostic, prognostic, and therapeutic potentials of DLX6-AS1 in clinical settings. Moreover, measurement of DLX6-AS1 levels in biofluids is an important step towards identification of non-invasive routes for diagnostic purposes.
Statements
Author contributions
MT and SGF wrote the draft and revised it. SN and MS collected the data and designed the figures and tables. All the authors read and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AnY.ChenX.-m.YangY.MoF.JiangY.SunD.-l.et al (2018). LncRNA DLX6-AS1 Promoted Cancer Cell Proliferation and Invasion by Attenuating the Endogenous Function of miR-181b in Pancreatic Cancer. Cancer Cel Int18 (1), 143. 10.1186/s12935-018-0643-7
2
BertoneP.StolcV.RoyceT. E.RozowskyJ. S.UrbanA. E.ZhuX.et al (2004). Global Identification of Human Transcribed Sequences with Genome Tiling Arrays. Science306 (5705), 2242–2246. 10.1126/science.1103388
3
ChenW.ZhangG.LiJ.ZhangX.HuangS.XiangS.et al (2018). CRISPRlnc: a Manually Curated Database of Validated sgRNAs for lncRNAs. Nucleic Acids Res.47 (D1), D63–D68. 10.1093/nar/gky904
4
ChengL.WangP.TianR.WangS.GuoQ.LuoM.et al (2018). LncRNA2Target v2.0: a Comprehensive Database for Target Genes of lncRNAs in Human and Mouse. Nucleic Acids Res.47 (D1), D140–D144. 10.1093/nar/gky1051
5
DeyB. K.MuellerA. C.DuttaA. (2014). Long Non-coding RNAs as Emerging Regulators of Differentiation, Development, and Disease. Transcription5 (4), e944014. 10.4161/21541272.2014.944014
6
DingX. Z.ZhangS. Q.DengX. L.QiangJ. H. (2021). Serum Exosomal lncRNA DLX6-AS1 Is a Promising Biomarker for Prognosis Prediction of Cervical Cancer. Technol. Cancer Res. Treat.20, 1533033821990060. 10.1177/1533033821990060
7
DuC.WangY.ZhangY.ZhangJ.ZhangL.LiJ. (2020). LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-Negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis. Cel Transpl.29, 963689720929983. 10.1177/0963689720929983
8
FangC.XuL.HeW.DaiJ.SunF. (2019). Long Noncoding RNA DLX6-AS1 Promotes Cell Growth and Invasiveness in Bladder Cancer via Modulating the miR-223-Hsp90b1 axis. Cell Cycle18 (23), 3288–3299. 10.1080/15384101.2019.1673633
9
FaticaA.BozzoniI. (2014). Long Non-coding RNAs: New Players in Cell Differentiation and Development. Nat. Rev. Genet.15 (1), 7–21. 10.1038/nrg3606
10
FengJ.BiC.ClarkB. S.MadyR.ShahP.KohtzJ. D. (2006). The Evf-2 Noncoding RNA Is Transcribed from the Dlx-5/6 Ultraconserved Region and Functions as a Dlx-2 Transcriptional Coactivator. Genes Dev.20 (11), 1470–1484. 10.1101/gad.1416106
11
FuX.TianY.KuangW.WenS.GuoW. (2019). Long Non-coding RNA DLX6-AS1 Silencing Inhibits Malignant Phenotypes of Gastric Cancer Cells. Exp. Ther. Med.17 (6), 4715–4722. 10.3892/etm.2019.7521
12
GongJ.LiuW.ZhangJ.MiaoX.GuoA.-Y. (2014). lncRNASNP: a Database of SNPs in lncRNAs and Their Potential Functions in Human and Mouse. Nucleic Acids Res.43 (D1), D181–D186. 10.1093/nar/gku1000
13
GuoJ.ChenZ.JiangH.YuZ.PengJ.XieJ.et al (2019). The lncRNA DLX6-AS1 Promoted Cell Proliferation, Invasion, Migration and Epithelial-To-Mesenchymal Transition in Bladder Cancer via Modulating Wnt/β-Catenin Signaling Pathway. Cancer Cel Int19, 312. 10.1186/s12935-019-1010-z
14
GuttmanM.AmitI.GarberM.FrenchC.LinM. F.FeldserD.et al (2009). Chromatin Signature Reveals over a Thousand Highly Conserved Large Non-coding RNAs in Mammals. Nature458 (7235), 223–227. 10.1038/nature07672
15
HanJ. Y.GuoS.WeiN.XueR.LiW.DongG.et al (2020). ciRS-7 Promotes the Proliferation and Migration of Papillary Thyroid Cancer by Negatively Regulating the miR-7/epidermal Growth Factor Receptor axis. Biomed. Res. Int.2020, 9875636. 10.1155/2020/9875636
16
HuangY.NiR.WangJ.LiuY. (2019). Knockdown of lncRNA DLX6-AS1 Inhibits Cell Proliferation, Migration and Invasion while Promotes Apoptosis by Downregulating PRR11 Expression and Upregulating miR-144 in Non-small Cell Lung Cancer. Biomed. Pharmacother.109, 1851–1859. 10.1016/j.biopha.2018.09.151
17
IgnarskiM.IslamR.MüllerR.-U. (2019). Long Non-coding RNAs in Kidney Disease. Ijms20 (13), 3276. 10.3390/ijms20133276
18
IyerM. K.NiknafsY. S.MalikR.SinghalU.SahuA.HosonoY.et al (2015). The Landscape of Long Noncoding RNAs in the Human Transcriptome. Nat. Genet.47 (3), 199–208. 10.1038/ng.3192
19
JiaP.WeiE.LiuH.WuT.WangH. (2020). Silencing of Long Non‐coding RNA DLX6‐AS1 Weakens Neuroblastoma Progression by the miR ‐513c‐5p/PLK4 axis. IUBMB Life72 (12), 2627–2636. 10.1002/iub.2392
20
KongL.ZhangC. (2020). LncRNA DLX6-AS1 Aggravates the Development of Ovarian Cancer via Modulating FHL2 by Sponging miR-195-5p. Cancer Cel Int20, 370. 10.1186/s12935-020-01452-z
21
KongW. Q.LiangJ. J.DuJ.YeZ. X.GaoP.LiangY. L. (2020). Long Noncoding RNA DLX6-AS1 Regulates the Growth and Aggressiveness of Colorectal Cancer Cells via Mediating miR-26a/EZH2 Axis. Cancer Biother. Radiopharm.36 (9), 753–764. 10.1089/cbr.2020.3589
22
LeiX.YangS.YangY.ZhangJ.WangY.CaoM. (2019). Long Noncoding RNA DLX6-AS1 Targets miR-124-3p/CDK4 to Accelerate Ewing's Sarcoma. Am. J. Transl Res.11 (10), 6569–6576.
23
LiC.WangS.YangC. (2020). RETRACTED: Long Non-coding RNA DLX6-AS1 Regulates Neuroblastoma Progression by Targeting YAP1 via miR-497-5p. Life Sci.252, 117657. 10.1016/j.lfs.2020.117657
24
LiD.TangX.LiM.ZhengY. (2019). Long Noncoding RNA DLX6‐AS1 Promotes Liver Cancer by Increasing the Expression of WEE1 via Targeting miR‐424‐5p. J. Cel Biochem120 (8), 12290–12299. 10.1002/jcb.28493
25
LiX.ZhangH.WuX. (2019). Long Noncoding RNA DLX6-AS1 Accelerates the Glioma Carcinogenesis by Competing Endogenous Sponging miR-197-5p to Relieve E2F1. Gene686, 1–7. 10.1016/j.gene.2018.10.065
26
LiY.LiX.YangY.LiM.QianF.TangZ.et al (2020). TRlnc: a Comprehensive Database for Human Transcriptional Regulatory Information of lncRNAs. Brief. Bioinformatics22 (2), 1929–1939. 10.1093/bib/bbaa011
27
LiangY.ZhangC.-D.ZhangC.DaiD.-Q. (2020). DLX6-AS1/miR-204-5p/OCT1 Positive Feedback Loop Promotes Tumor Progression and Epithelial-Mesenchymal Transition in Gastric Cancer. Gastric Cancer23 (2), 212–227. 10.1007/s10120-019-01002-1
28
LiuX.PengD.CaoY.ZhuY.YinJ.ZhangG.et al (2020). Upregulated lncRNA DLX6-AS1 Underpins Hepatocellular Carcinoma Progression via the miR-513c/Cul4A/ANXA10 axis. Cancer Gene Ther.28 (5), 486–501. 10.1038/s41417-020-00233-0
29
LiuY.LiuX.ZhangX.DengJ.ZhangJ.XingH. (2020). lncRNA DLX6-AS1 Promotes Proliferation of Laryngeal Cancer Cells by Targeting the miR-26a/TRPC3 Pathway. CmarVol. 12, 2685–2695. 10.2147/cmar.s237181
30
LongJ.BaiY.YangX.LinJ.YangX.WangD.et al (2019). Construction and Comprehensive Analysis of a ceRNA Network to Reveal Potential Prognostic Biomarkers for Hepatocellular Carcinoma. Cancer Cel Int19, 90. 10.1186/s12935-019-0817-y
31
LoskoM.KotlinowskiJ.JuraJ. (2016). Long Noncoding RNAs in Metabolic Syndrome Related Disorders. Mediators Inflamm.2016, 5365209. 10.1155/2016/5365209
32
MattickJ. S. (2001). Non‐coding RNAs: the Architects of Eukaryotic Complexity. EMBO Rep.2 (11), 986–991. 10.1093/embo-reports/kve230
33
MattickJ. S. (2009). The Genetic Signatures of Noncoding RNAs. Plos Genet.5 (4), e1000459. 10.1371/journal.pgen.1000459
34
MiaoY.-R.LiuW.ZhangQ.GuoA.-Y. (2017). lncRNASNP2: an Updated Database of Functional SNPs and Mutations in Human and Mouse lncRNAs. Nucleic Acids Res.46 (D1), D276–D280. 10.1093/nar/gkx1004
35
NecsuleaA.SoumillonM.WarneforsM.LiechtiA.DaishT.ZellerU.et al (2014). The Evolution of lncRNA Repertoires and Expression Patterns in Tetrapods. Nature505 (7485), 635–640. 10.1038/nature12943
36
NingS.ZhangJ.WangP.ZhiH.WangJ.LiuY.et al (2015). Lnc2Cancer: a Manually Curated Database of Experimentally Supported lncRNAs Associated with Various Human Cancers. Nucleic Acids Res.44 (D1), D980–D985. 10.1093/nar/gkv1094
37
OkazakiY.FurunoM.KasukawaT.AdachiJ.BonoH.KondoS.et al (2002). Analysis of the Mouse Transcriptome Based on Functional Annotation of 60,770 Full-Length cDNAs. Nature420 (6915), 563–573. 10.1038/nature01266
38
PastoriC.WahlestedtC. (2012). Involvement of Long Noncoding RNAs in Diseases Affecting the central Nervous System. RNA Biol.9 (6), 860–870. 10.4161/rna.20482
39
QianY.SongW.WuX.HouG.WangH.HangX.et al (2021). DLX6 Antisense RNA 1 Modulates Glucose Metabolism and Cell Growth in Gastric Cancer by Targeting microRNA-4290. Dig. Dis. Sci.66 (2), 460–473. 10.1007/s10620-020-06223-4
40
SahuA.SinghalU.ChinnaiyanA. M. (2015). Long Noncoding RNAs in Cancer: From Function to Translation. Trends Cancer1 (2), 93–109. 10.1016/j.trecan.2015.08.010
41
SunW.ZhangL.YanR.YangY.MengX. (2019). LncRNA DLX6-AS1 Promotes the Proliferation, Invasion, and Migration of Non-small Cell Lung Cancer Cells by Targeting the miR-27b-3p/GSPT1 axis. OttVol. 12, 3945–3954. 10.2147/ott.s196865
42
TakahashiK.YanI.HagaH.PatelT. (2014). Long Noncoding RNA in Liver Diseases. Hepatology60 (2), 744–753. 10.1002/hep.27043
43
UchidaS.DimmelerS. (2015). Long Noncoding RNAs in Cardiovascular Diseases. Circ. Res.116 (4), 737–750. 10.1161/circresaha.116.302521
44
WanP.SuW.ZhuoY. (2017). The Role of Long Noncoding RNAs in Neurodegenerative Diseases. Mol. Neurobiol.54 (3), 2012–2021. 10.1007/s12035-016-9793-6
45
WawrzyniakO.ZarębskaŻ.RolleK.Gotz-WięckowskaA. (2018). Circular and Long Non-coding RNAs and Their Role in Ophthalmologic Diseases. Acta Biochim. Pol.65 (4), 497–508. 10.18388/abp.2018_2639
46
WiluszJ. E.SunwooH.SpectorD. L. (2009). Long Noncoding RNAs: Functional Surprises from the RNA World. Genes Dev.23 (13), 1494–1504. 10.1101/gad.1800909
47
WuD. M.ZhengZ. H.ZhangY. B.FanS. H.ZhangZ. F.WangY. J.et al (2019). Down-regulated lncRNA DLX6-AS1 Inhibits Tumorigenesis through STAT3 Signaling Pathway by Suppressing CADM1 Promoter Methylation in Liver Cancer Stem Cells. J. Exp. Clin. Cancer Res.38 (1), 237. 10.1186/s13046-019-1239-3
48
WuP.ZuoX.DengH.LiuX.LiuL.JiA. (2013). Roles of Long Noncoding RNAs in Brain Development, Functional Diversification and Neurodegenerative Diseases. Brain Res. Bull.97, 69–80. 10.1016/j.brainresbull.2013.06.001
49
WuQ.MaJ.MengW.HuiP. (2020). DLX6-AS1 Promotes Cell Proliferation, Migration and EMT of Gastric Cancer through FUS-Regulated MAP4K1. Cancer Biol. Ther.21 (1), 17–25. 10.1080/15384047.2019.1647050
50
XieF.XieG.SunQ. (2020). Long Noncoding RNA DLX6-AS1 Promotes the Progression in Cervical Cancer by Targeting miR-16-5p/ARPP19 Axis. Cancer Biother. Radiopharm.35 (2), 129–136. 10.1089/cbr.2019.2960
51
YangB.JiaL.RenH.JinC.RenQ.ZhangH.et al (2020). LncRNA DLX6-AS1 Increases the Expression of HIF-1α and Promotes the Malignant Phenotypes of Nasopharyngeal Carcinoma Cells via Targeting MiR-199a-5p. Mol. Genet. Genomic Med.8 (1), e1017. 10.1002/mgg3.1017
52
YangJ.YeZ.MeiD.GuH.ZhangJ. (2019). Long Noncoding RNA DLX6-AS1 Promotes Tumorigenesis by Modulating miR-497-5p/FZD4/FZD6/Wnt/β-Catenin Pathway in Pancreatic Cancer. CmarVol. 11, 4209–4221. 10.2147/cmar.s194453
53
YangQ.SunJ.MaY.ZhaoC.SongJ. (2019). LncRNA DLX6-AS1 Promotes Laryngeal Squamous Cell Carcinoma Growth and Invasion through Regulating miR-376c. Am. J. Transl Res.11 (11), 7009–7017.
54
ZengX.HuZ.KeX.TangH.WuB.WeiX.et al (2017). Long Noncoding RNA DLX6-AS1 Promotes Renal Cell Carcinoma Progression via miR-26a/PTEN axis. Cell Cycle16 (22), 2212–2219. 10.1080/15384101.2017.1361072
55
ZhangJ. J.XuW. R.ChenB.WangY. Y.YangN.WangL. J.et al (2019). The Up-Regulated lncRNA DLX6-AS1 in Colorectal Cancer Promotes Cell Proliferation, Invasion and Migration via Modulating PI3K/AKT/mTOR Pathway. Eur. Rev. Med. Pharmacol. Sci.23 (19), 8321–8331. 10.26355/eurrev_201910_19143
56
ZhangL.HeX.JinT.GangL.JinZ. (2017). Long Non-coding RNA DLX6-AS1 Aggravates Hepatocellular Carcinoma Carcinogenesis by Modulating miR-203a/MMP-2 Pathway. Biomed. Pharmacother.96, 884–891. 10.1016/j.biopha.2017.10.056
57
ZhangN.MengX.MeiL.ZhaoC.ChenW. (2019). LncRNA DLX6‐AS1 Promotes Tumor Proliferation and Metastasis in Osteosarcoma through Modulating miR‐641/HOXA9 Signaling Pathway. J. Cel Biochem120 (7), 11478–11489. 10.1002/jcb.28426
58
ZhangR. M.TangT.YuH. M.YaoX. D. (2018). LncRNA DLX6-AS1/miR-129-5p/DLK1 axis Aggravates Stemness of Osteosarcoma through Wnt Signaling. Biochem. Biophys. Res. Commun.507 (1), 260–266. 10.1016/j.bbrc.2018.11.019
59
ZhangX.GuoH.BaoY.YuH.XieD.WangX. (2019). Exosomal Long Non-coding RNA DLX6-AS1 as a Potential Diagnostic Biomarker for Non-small Cell Lung Cancer. Oncol. Lett.18 (5), 5197–5204. 10.3892/ol.2019.10892
60
ZhaoH.XuQ. (2020). Long Non‐coding RNA DLX6‐AS1 Mediates Proliferation, Invasion and Apoptosis of Endometrial Cancer Cells by Recruiting p300/E2F1 in DLX6 Promoter Region. J. Cel. Mol. Med.24 (21), 12572–12584. 10.1111/jcmm.15810
61
ZhaoJ.LiuH. R. (2019). Down-regulation of Long Noncoding RNA DLX6-AS1 Defines Good Prognosis and Inhibits Proliferation and Metastasis in Human Epithelial Ovarian Cancer Cells via Notch Signaling Pathway. Eur. Rev. Med. Pharmacol. Sci.23 (8), 3243–3252. 10.26355/eurrev_201904_17684
62
ZhaoP.GuanH.DaiZ.MaY.ZhaoY.LiuD. (2019). Long Noncoding RNA DLX6-AS1 Promotes Breast Cancer Progression via miR-505-3p/RUNX2 axis. Eur. J. Pharmacol.865, 172778. 10.1016/j.ejphar.2019.172778
63
ZhaoY.-H.WangZ.ZhangN.CuiT.ZhangY.-H. (2020). Effect of ciRS-7 Expression on clear Cell Renal Cell Carcinoma Progression. Chin. Med. J.133 (17), 2084–2089. 10.1097/cm9.0000000000000867
64
ZhaoZ.LiangS.SunF. (2020). LncRNA DLX6-AS1 Promotes Malignant Phenotype and Lymph Node Metastasis in Prostate Cancer by Inducing LARGE Methylation. Front. Oncol.10, 1172. 10.3389/fonc.2020.01172
65
ZhuX.MaX.ZhaoS.CaoZ. (2021). DLX6‐AS1 Accelerates Cell Proliferation through Regulating miR ‐497‐5p/SNCG Pathway in Prostate Cancer. Environ. Toxicol.36 (3), 308–319. 10.1002/tox.23036
Summary
Keywords
DLX6-AS1, non-coding RNA, lncRNA, cancer, miRNA 3
Citation
Ghafouri-Fard S, Najafi S, Hussen BM, Ganjo AR, Taheri M and Samadian M (2022) DLX6-AS1: A Long Non-coding RNA With Oncogenic Features. Front. Cell Dev. Biol. 10:746443. doi: 10.3389/fcell.2022.746443
Received
23 July 2021
Accepted
04 February 2022
Published
25 February 2022
Volume
10 - 2022
Edited by
Ri Cui, Wenzhou Medical University, China
Reviewed by
Hamed Shoorei, Birjand University of Medical Sciences, Iran
Huanlei Huang, Guangdong Provincial People’s Hospital, China
Updates
Copyright
© 2022 Ghafouri-Fard, Najafi, Hussen, Ganjo, Taheri and Samadian.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mohammad Taheri, Mohammad.taheri@uni-jena.de; Mohammad Samadian, mdsamadian@gmail.com
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.